Crohn’s Disease Market Size, Share, Trends, Industry Analysis Report

Market Size

The global Crohn's disease market size, valued at USD 9.6 billion in 2025, is projected to reach USD 10.3 billion in 2026 and USD 18.1 billion by 2035, representing a CAGR of 6.5% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of drug class, biologics hold the highest share of the current market, and this trend is unlikely to change in the future.
• Based on the route of administration, the subcutaneous route dominates (more than 40%) the future market (2035).
• With respect to the distribution channel, hospital pharmacies capture most of the current Crohn's disease market share.
• In terms of geographical regions, North America holds the highest market share (around 70%) in the year 2035.

Key Market Statistics

• Market Size in 2026: $10.3 Billion
• Estimated Market Size in 2035: $18.1 Billion
• CAGR (2026-2035): 6.5%
• North America: Largest market in 2026
• Asia-Pacific: Fastest growing region

Market Introduction

Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract. It may affect any segment of the digestive system, although the small intestine and colon are the sites most commonly involved. The disease typically follows a relapsing and remitting course, characterized by periods of symptom worsening followed by temporary improvement.

The clinical presentation of Crohn's disease varies considerably across patients, ranging from mild gastrointestinal discomfort to severe and debilitating illness. Common manifestations include abdominal pain, diarrhea, fatigue, weight loss, and reduced appetite, while impaired nutrient absorption may also lead to malnutrition. Notably, in more advanced or uncontrolled cases, the disease can result in serious complications, such as intestinal strictures, fistulas, and persistent inflammation. This wide variation in symptoms and severity often makes diagnosis, monitoring, and management more complex.

The treatment landscape for Crohn's disease is evolving rapidly, with increasing emphasis on targeted and individualized therapeutic approaches. Conventional therapies, including amino salicylates, corticosteroids, and immunomodulators, continue to play an important role in disease control. At the same time, biologic therapies have become a central component of treatment for many patients, particularly those with moderate to severe disease. Newer drug classes, such as JAK inhibitors and other advanced therapies, are further broadening the treatment landscape. Overall, treatment strategies are now focused not only on symptom relief but also on deeper disease control, complication prevention, and improved long-term outcomes.

Currently Approved Drugs for Crohn's Disease

A number of biologics are approved for the treatment of Crohn's disease. The most recent biologic to receive approval is Eli Lilly's Omvoh, an IL-23 inhibitor targeting moderate to severe Crohn's disease. The FDA approval came in January 2025.

In May 2023, FDA granted approval to AbbVie's Rinvoq, the first once-daily pill for moderate to severe Crohn's disease. The table below lists some of the approved drugs for this indication.

Market Segmentation

Based on the research, we have segmented the Crohn's Disease Market Report into drug class, route of administration, distribution channel, and geographical regions.

By Drug Class

• Biologics
• Amino salicylates
• Antibiotics
• Corticosteroids
• Immunomodulators
• Others

By Route of Administration

• Subcutaneous
• Intravenous
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geographical Regions

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa
  • Saudi Arabia
  • Israel
  • United Arab Emirates
  • Egypt
• Latin America
  • Brazil
  • Mexico
  • Argentina

Crohn's Disease Market Key Insights

What are the Drivers for Crohn's Disease Market Growth?

• Rising Prevalence of Crohn's Disease: The rising prevalence of Crohn's disease represents a major market opportunity within this domain. Notably, in 2023, an estimated 1 million patients were living with Crohn's disease in the US alone. This increasing patient burden is expected to drive demand for effective therapeutic solutions across multiple care settings. As awareness and diagnosis improve, the need for advanced therapies is likely to grow further, supporting overall market expansion.
• Advancements in Targeted Biologic Therapies: Advancements in targeted biologic therapies are creating substantial opportunities in the Crohn's disease market by improving treatment precision and clinical outcomes. These therapies are increasingly preferred for patients with moderate to severe diseases because they provide better disease control and fewer limitations than older treatment options. Their continued development is encouraging innovation, strengthening physician adoption, and contributing to higher market value.
• Rising Adoption of JAK Inhibitors and Immunomodulators: The rising adoption of JAK inhibitors and immunomodulators offers a substantial market opportunity in Crohn's disease management, providing key alternatives for patients who do not respond adequately to conventional therapies. Their expanding use reflects the growing need for more flexible and effective treatment approaches in Crohn's disease management.

What are the Restraints for Crohn's Disease Market Growth?

• High Treatment Costs: The high cost associated with the treatment of Crohn's disease limits patient access and hinders adoption of advanced therapies. For instance, biologic therapies such as infliximab and ustekinumab are associated with annual treatment costs ranging from USD 45,000 to USD 90,000. These treatments often cost significantly more than conventional medicines, which limits affordability for many patients and healthcare systems.
• Complex Diagnosis: The challenges in the diagnosis of Crohn's disease and disease variability present a substantial restraint to the market growth. Notably, disease severity and progression vary widely from patient to patient, making treatment selection more complex. This variability can delay timely therapy initiation and reduce the consistency of treatment outcomes. As a result, diagnostic challenges and heterogeneous disease patterns continue to limit market growth and therapeutic efficiency.
• Adverse Effects and Safety Concerns: The current treatment landscape is associated with several side effects, including infection risk, immune suppression, and other long-term complications. These safety issues make both physicians and patients hesitant to initiate or continue treatment, thereby slowing adoption and restricting overall market growth.

What are Recent Crohn's Disease Market Trends?

• Launch of Biosimilars: The launch of biosimilars is expanding treatment options for patients with Crohn's disease (CD) by improving access to advanced biologic therapies. Biosimilars, such as Wezlan, Amjevita, and Avsola have further strengthened the available treatment landscape for patients with moderate to severe Crohn's disease. The growing availability of these biosimilars is expected to enhance affordability and support broader adoption of biologic therapy.
• Development of Cell Therapy and Exploration of Novel Pathways: In the past few years, drug developers have shifted their focus towards new modalities, including cell therapies, for patients with severe or treatment-refractory disease. The early clinical studies suggest that stem cell approaches may help reduce inflammation, promote mucosal healing, and improve fistula closure. At the same time, researchers are exploring novel pathways, such as IL-23- and integrin-targeted mechanisms to improve outcomes beyond conventional anti-TNF therapy.

Recent Developments in Crohn's Disease Market

• In May 2026, Johnson & Johnson announced the USFDA approval of Stelara® for the treatment of patients (two years and older) with moderately to severely active Crohn's disease.
• In March 2026, Teva Pharmaceuticals secured USD 400 million from Blackstone Life Sciences aimed to advance the clinical development of duvakitug intended for the treatment of inflammatory bowel diseases, including Crohn's disease.
• In February 2026, Agomab initiated an initial public offering to finance a Phase 2b trial of Ontunisertib, a candidate therapy for the treatment of Crohn's disease.
• In May 2025, Bio-Thera Solutions in partnership with Hikma Pharmaceuticals announced the USFDA approval of STARJEMZA (ustekinumab-hmny), a biosimilar of Stelara®, intended for the treatment of chronic inflammatory and autoimmune conditions, including Crohn's disease.

Industry Experts on Crohn's Disease Market

The Crohn's disease drugs market is projected to expand rapidly, driven by the rising disease prevalence and the lack of effective treatment approaches. Validating this trend, Jean-Frederic Colombel (Professor), stated that, "A study we conducted with the Crohn's & Colitis Foundation in the USA 2 years ago revealed that approximately 50% of patients with CD had to wait more than 2 years to receive their diagnosis."

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:

• Founder, Public Hospital, US
• Gastroenterology and Assistant Professor of Medicine, Public University, US
• Gastroenterologist, Mid-sized Company, Germany
• Clinical Pharmacy Coordinator, Non-Profit Organization, US
• Gastroenterologist and Head of the Clinical Pharmacology, Public University, Portugal
• Gastroenterologist, Public Hospital, Spain
• Gastroenterologist, Public Hospital, Germany
• Gastroenterologist, Public Hospital, US
• Gastroenterologist, Public University, US
• Assistant Professor, Public University, US

Market Share Insights

Which Type of Drug Class Accounts for the Largest Share in Crohn's Disease Market?

This segment highlights the distribution of market value for Crohn's disease across various drug classes, such as biologics, amino salicylates, antibiotics, corticosteroids, immunomodulators and others.

Currently, the biologics segment captures the majority of the Crohn's disease market share. This dominance is due to their established role as the standard of care for patients with moderate-to-severe Crohn's disease, where conventional therapies, such as corticosteroids and immunomodulators are often insufficient for long-term disease control. Their ability to target specific inflammatory pathways, reduce steroid dependence, and support long-term remission has made them a preferred treatment option.

Moreover, continued physician confidence, strong treatment guideline support, broad reimbursement coverage across developed markets, and the availability of multiple approved biologic classes have reinforced their widespread adoption. Furthermore, the increasing preference for early biologic intervention under treat-to-target management strategies has expanded their use beyond refractory patients, strengthening the segment's market leadership.

Biologics are also expected to register the highest CAGR during the forecast period. This accelerated growth is due to continued innovation in targeted mechanisms, especially IL-23 inhibitors. Recent approvals of therapies such as SKYRIZI, OMVOH and TREMFYA have expanded treatment options for patients who have failed older anti-TNF therapies. This creates opportunities for companies developing biologics with better efficacy, durable remission, convenient dosing and stronger positioning in earlier lines of treatment.

Market Share by Route of Administration: Subcutaneous Route to Dominate Crohn's Disease Market

Based on the route of administration, the global market is segmented into subcutaneous, intravenous, and oral routes.

Currently, the subcutaneous sub-segment is likely to capture the majority of the Crohn's disease market size. This is due to the fact that most high-value biologic therapies used for long-term disease control are administered subcutaneously during maintenance treatment. This route is well established across major marketed products, including HUMIRA, STELARA, SKYRIZI, and newer subcutaneous formulations such as ZYMFENTRA and ENTYVIO Pen. Moreover, unlike the intravenous route of administration, which often requires complex and patient-specific body weight, subcutaneous injections frequently use a standard fixed dose, minimizing the risk of dosing errors. In addition, subcutaneous formulations offer greater convenience through self-administration at home, reducing hospital visits and lowering treatment burden for patients.

Moreover, it is worth highlighting that, as per Crohn's disease market analysis, the market share for oral sub-segment is likely to grow at a relatively higher CAGR (8.1%) during the forecast period. This trend is supported by the growing development of targeted oral therapies that offer a more convenient alternative to injectable treatments. Pharmaceutical companies are increasingly investing in oral small molecules and other novel therapies that can improve patient compliance, simplify long-term disease management, and reduce dependence on healthcare facility-based administration.

As the pipeline of oral therapies expands and more products demonstrate favorable efficacy and safety profiles, companies that focus on differentiated oral formulations and earlier treatment positioning are likely to benefit from the increasing demand for patient-friendly Crohn's disease therapies.

Which Distribution Channel Holds the Largest Share in the Market?

Based on the distribution channel, the global market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.

According to our market analysis, currently hospital pharmacies occupy the highest market share in Crohn's disease market. This is because advanced therapies, particularly biologic agents and immunomodulators, require professional administration, close clinical monitoring, and specialized infusion services that are most efficiently delivered in a hospital setting. Moreover, these high-cost, complex treatments often involve initial dose supervision to manage potential adverse reactions, dose adjustments based on real-time patient response, and integrated care coordination with gastroenterologists. For pharmaceutical companies, this dynamic underscores the importance of building strong partnerships with hospital networks and developing targeted hospital sales and medical affairs strategies to optimize market access.

On the contrary, the online pharmacy segment is likely to grow at a higher CAGR during the forecast period. This is due to the fact that Crohn's disease frequently involves unpredictable flare-ups, fatigue, and mobility challenges that make repeated in-person pharmacy visits burdensome. Online platforms offer discreet home delivery, auto-refill programs, and 24/7 access, significantly reducing treatment disruptions. Moreover, patients benefit from price transparency, copay assistance, and integrated telehealth services that improve adherence, with these advantages amplified by post-pandemic digital adoption and regulatory support for e-prescriptions.

Regional Analysis: Which Regions are Showing the Fastest Growth in Crohn's Disease Market?

North America Market: Securing the Highest Share

In terms of geographical regions, the global market is distributed across North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.

According to our Crohn's disease market forecast, North America is likely to capture the majority (around 70%) of the Crohn's disease market share in the current year, and this trend is unlikely to change. The region's dominance is driven by its advanced healthcare infrastructure, high diagnosis rates, and widespread adoption of biologics supported by favorable reimbursement policies and strong access to specialist care.

The region's leadership is further reinforced by the significant disease burden in the US, where the Centers for Disease Control and Prevention (CDC) estimates that 2.4-3.1 million people are living with inflammatory bowel disease, sustaining demand for long-term treatment. Additionally, the increasing adoption of early diagnosis and treat-to-target care strategies continues to drive the use of advanced therapies, maintaining North America's dominant position in the global market.

Asia-Pacific: An Emerging Growth Spot

The market in Asia-Pacific is likely to grow at a high CAGR during the forecast period till 2035. This is owing to expanding healthcare infrastructure, increased biologic therapy availability, and regulatory approvals of newer treatments, including oral B-cell inhibitors. Further, rising awareness among gastroenterologists and increased investment in IBD clinical trials is accelerating treatment adoption among patients.

Scope of Crohn's Disease Market Report